EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd KRW 12,301, price KRW 4,845, upside +153.9%, quality 78 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · KR

DB Some data Sep 24, 2026

Daishin Balance No.8 Special Purpose Acquisition Co. Ltd

336570 · KQ

Strongly undervaluedStrong Fair Value upside with high Quality.

✓Fair value 12,301 KRW · Strongly undervalued (+154%)
✓Quality 78/100
!Mixed Growth (revenue 3y +24.4 %/yr)
✓Highly profitable · 21.1% net margin (TTM)
✓Low debt · generates free cash flow
·1.03% dividend yield
✓Ranks above peers (9/10)
✓Wide moat 83/100
!Evidence only medium, so the estimate is less certain
!Weak on dividend: 21 out of 100
Watch Daishin Balance No.8 Special Purpose Acquisition Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

14,586 KRW 1,974 KRW Fair Value 12,301 KRW Nov 2020 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 1,974 KRW – 14,586 KRW · fair‑value band 7,402 KRW – 21,179 KRW · the 4,845 KRW price screens below the 12,301 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow Daishin Balance No.8 Special Purpose Acquisition Co. in your weekly email

Every Wednesday you see whether Daishin Balance No.8 Special Purpose Acquisition Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

WON TECH Co.,Ltd. engages in the production and sale of laser and energy-based equipment in South Korea and internationally. The company offers aesthetics, skincare, homecare, and surgical usage equipment.

Show more

WON TECH Co.,Ltd. engages in the production and sale of laser and energy-based equipment in South Korea and internationally. The company offers aesthetics, skincare, homecare, and surgical usage equipment. It also provides products for the treatments, including face lifting and tightening, body contouring, skin rejuvenation, tattoo removal, scars and striae, vascular lesions, hair removal, and surgical. The company was formerly known as WONTECHnology and changed its name to WON TECH Co.,Ltd. in 2013. WON TECH Co.,Ltd. was founded in 1999 and is headquartered in Daejeon, South Korea.

Stock analysis

Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570) currently trades at 4,845 KRW, while our model-based Fair Value estimate is 12,301 KRW, implying the stock looks roughly 60.6% undervalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of 16,554 KRW per share, and 22 of the 26 models we run sit above the 4,845 KRW price.

Bear case: the Economic Profit group reads lowest at 3,258 KRW, and 4 of the 26 models stay below the price. Evidence for this calculation is medium.

Scenario range: 7,402 KRW (bear) to 21,179 KRW (bull), the price of 4,845 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 78/100 (high quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Daishin Balance No.8 Special Purpose Acquisition Co. Ltd reported revenue of 157B KRW in FY2025 versus 51.1B KRW in FY2021, a compound +32.4%/yr. Reported net income was 35.2B KRW in FY2025.

Key figures

Market cap 436B KRW (≈ $320M) · P/S ratio 2.81 · Dividend yield 1.0% · Net margin 22.5% · Return on equity 22.7% · Return on assets (EBIT) 21.7% · Operating margin 27.8% · Revenue (TTM) 160B KRW.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 53 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at 154%, 336570 screens cheaper than that median.

Fair Value models

Bear 7,402 KRW Fair Value 12,301 KRW Bull 21,179 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF 8,338 KRW 12,004 KRW 22,960 KRW 77
Growth DCF 7,834 KRW 13,275 KRW 21,825 KRW 76
EPV 4,558 KRW 5,130 KRW 5,607 KRW 74
All 26 models by family
DCF Models
FCF DCF 8,338 KRW 12,004 KRW 22,960 KRW 77
Owner Earnings 5,961 KRW 11,964 KRW 23,102 KRW 72
5Y Revenue Exit 5,671 KRW 8,919 KRW 15,666 KRW 70
5Y EBITDA Exit 7,386 KRW 12,382 KRW 22,163 KRW 72
5Y P/E Exit 7,447 KRW 15,457 KRW 26,244 KRW 68
10Y Revenue Exit 6,458 KRW 12,197 KRW 15,398 KRW 67
10Y EBITDA Exit 7,743 KRW 15,564 KRW 28,834 KRW 65
10Y P/E Exit 7,784 KRW 15,685 KRW 28,369 KRW 61
Earnings-Based
Graham-Dodd 2,699 KRW 18,824 KRW 26,416 KRW 63
Lynch FV 8,497 KRW 12,138 KRW 15,780 KRW 61
PEG = 1.0 8,497 KRW 12,138 KRW 15,780 KRW 57
EPV 4,558 KRW 5,130 KRW 5,607 KRW 74
Dividend Discount
Gordon GGM 389.57 KRW 702.00 KRW 966.39 KRW 68
DDM Multi-Stage 389.57 KRW 641.26 KRW 749.91 KRW 67
Multiples
P/E Multiple 6,550 KRW 8,733 KRW 10,916 KRW 63
P/S Multiple 4,640 KRW 6,186 KRW 7,733 KRW 58
P/B Multiple 5,061 KRW 6,748 KRW 8,435 KRW 55
EV/EBIT 7,791 KRW 10,267 KRW 12,742 KRW 66
EV/EBITDA 6,825 KRW 8,978 KRW 11,132 KRW 67
EV/Revenue 4,076 KRW 5,667 KRW 7,258 KRW 54
Asset-Based
NCAV (Graham) 886.81 KRW 1,188 KRW 1,774 KRW 54
Growth DCF
Growth DCF 7,834 KRW 13,275 KRW 21,825 KRW 76
Rev-Margin DCF 6,010 KRW 10,155 KRW 18,506 KRW 70
Economic Profit
Residual Income 2,321 KRW 3,258 KRW 15,868 KRW 64
ROIC Compounder 5,659 KRW 7,949 KRW 10,759 KRW 71
Growth Earnings
Growth-Adj P/E 11,588 KRW 16,554 KRW 21,520 KRW 67

Open the full fair value analysis →

Notify me when 336570 reaches fair value

Put 336570 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 78/100

Of which business quality 78 · Market factors (momentum, volatility) 16

Profitability 80
Margins and returns on capital today
Quality Growth 79
Are margins and returns improving?
Cashflow 91
Earnings quality: real cash, not paper profit
Fin. Strength 89
Balance sheet, leverage, solvency risk
Investment 33
Disciplined investing over empire-building
Low Volatility 37
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 4
Distance to the 52-week high (market factor)
Net Issuance 74
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 90/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+36.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.4%
What shareholders gained per year (last 3 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 3 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+10.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year+9.7%
Dividend (yield on the price)1.0%
Profit margin 2021 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.0% → 33%

Growth Forecast

Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−5.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+18.5%
Yearly sales growth analysts expect, extended to five years.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −7.7% a year for the price and +16.0% for the forecasts.
Forecast 2026 (sales)+21.4%
Forecast 2027 (sales)+21.4%
Projected 2028 (sales)+19.0%
Projected 2029 (sales)+16.6%
Projected 2030 (sales)+14.1%

Watch 336570, get fair value alerts →

Compare Daishin Balance No.8 Special Purpose Acquisition Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 9/10 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 78 · Top 25%
Fair Value upside +154% · Top 25%
Profitability
Return on equity (TTM) 23% · Top 25%
Return on assets 14% · Top 25%
Net margin (TTM) 21% · Top 25%
Operating margin (TTM) 28% · Top 25%
Growth and dividend
Revenue growth 8% · Above median
Dividend yield (TTM) 1.0% · Below median
Balance sheet
Debt / equity 0.00× · Lowest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/FCF 0.0× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)100 · sector 10
FUTURE (revenue growth)38 · sector 31
PAST (return on equity)91 · sector 7
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)21 · sector 40

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $101.07 $74.79 −26%
Medtronic plc MDT $89.30 $65.57 −27%
Stryker Corporation SYK $269.75 $296.73 +10%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Daishin Balance No.8 Special Purpose Acquisition Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/336570

Frequently asked questions

Is Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 12,301 KRW versus a price of 4,845 KRW, about +154% upside (undervalued).
What is the fair value of 336570?
Our model-based fair value for Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 12,301 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 4,845 KRW.
What is the quality score of 336570?
Daishin Balance No.8 Special Purpose Acquisition Co. Ltd has a Quality Score of 78/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
Our model-based price target is the fair value of 12,301 KRW (as of Sep 24, 2026) from 26 valuation models. Cautious scenario 7,402 KRW, optimistic scenario 21,179 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Daishin Balance No.8 Special Purpose Acquisition Co. Ltd stock forecast for 2026?
Our models put fair value at 12,301 KRW, about +154% upside versus a price of 4,845 KRW (undervalued). Cautious scenario 7,402 KRW, optimistic scenario 21,179 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
Daishin Balance No.8 Special Purpose Acquisition Co. Ltd reported trailing-twelve-month revenue of about 160B KRW (latest available figure, as of Sep 24, 2026).
Does Daishin Balance No.8 Special Purpose Acquisition Co. Ltd pay a dividend?
Daishin Balance No.8 Special Purpose Acquisition Co. Ltd currently shows a dividend yield of about 1.03% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
For today's price to be fair in a discounted-cash-flow model, Daishin Balance No.8 Special Purpose Acquisition Co. Ltd would have to grow free cash flow by -5.8 % per year for five years (discount rate 11.2 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 4 years revenue grew +32.4 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 336570 use?
Our models discount Daishin Balance No.8 Special Purpose Acquisition Co. Ltd at 11.2 %: a base by market capitalisation (small), damped by beta 0.84, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Daishin Balance No.8 Special Purpose Acquisition Co. Ltd that is -5.8 % per year a year over ten years, using the same discount rate (11.2 %) and the same formula as our fair value.
How much growth has Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570) delivered so far?
Over the past 4 years revenue at Daishin Balance No.8 Special Purpose Acquisition Co. Ltd grew +32.4 % a year. The price currently implies -5.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570) growing?
The median revenue growth in the sector is +1.9 % a year. That is the yardstick for the growth priced into Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (-5.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The free-cash-flow yield on the price is 11.43 %: that much free cash flow Daishin Balance No.8 Special Purpose Acquisition Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.2 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Daishin Balance No.8 Special Purpose Acquisition Co. Ltd it is 12,301 KRW per share (as of Sep 24, 2026), against a price of 4,845 KRW. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Daishin Balance No.8 Special Purpose Acquisition Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 336570 trades below its calculated fair value: price 4,845 KRW, fair value 12,301 KRW, a gap of about +154% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 336570?
No. The price is what the market pays today (4,845 KRW); the fair value is what the company's own numbers justify (12,301 KRW). For Daishin Balance No.8 Special Purpose Acquisition Co. Ltd the two are 7,456 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Daishin Balance No.8 Special Purpose Acquisition Co. Ltd worth?
The market values Daishin Balance No.8 Special Purpose Acquisition Co. Ltd at about 436B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 4,845 KRW; our models calculate a fair value of 12,301 KRW per share.
What do the bullish and bearish scenarios say about 336570?
Our models span a range for Daishin Balance No.8 Special Purpose Acquisition Co. Ltd: cautious scenario 7,402 KRW, base 12,301 KRW, optimistic 21,179 KRW per share (as of Sep 24, 2026, price 4,845 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
Balance-sheet figures for Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (as of Sep 24, 2026): return on equity 22.7%, debt of 0.00 per unit of equity. They feed the Quality Score of 78/100, which measures business quality independently of the share price.
How far is 336570 from its 52-week high?
Daishin Balance No.8 Special Purpose Acquisition Co. Ltd trades at 4,845 KRW, about 53% below its 52-week high of 10,220 KRW and 11% above the low of 4,380 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 12,301 KRW is for.
Which stocks are comparable to Daishin Balance No.8 Special Purpose Acquisition Co. Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Daishin Balance No.8 Special Purpose Acquisition Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 4,845 KRW, calculated fair value 12,301 KRW (+154%), Quality Score 78/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 336570 calculated?
We run Daishin Balance No.8 Special Purpose Acquisition Co. Ltd through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 12,301 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. Daishin Balance No.8 Special Purpose Acquisition Co. Ltd currently trades 154 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The closing price on Sep 23, 2026 was 4,845 KRW. Our model-based fair value is 12,301 KRW, about +154% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Daishin Balance No.8 Special Purpose Acquisition Co. Ltd right now?
The rarer combination: high quality (78/100) AND below fair value. That earns a closer look rather than a quick verdict. The price is below even our cautious bear case (7,402 KRW). The market is more pessimistic than our downside scenario. The model range is unusually wide (7,402 KRW to 21,179 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd

How large is the market capitalisation of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The market capitalisation of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 436B KRW (≈ $320M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The price-to-sales ratio of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 2.81 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The dividend yield of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 1.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The net margin of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 22.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The return on equity (ROE) of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 22.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
On an EBIT basis the return on assets of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 21.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
The operating margin of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 27.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
Revenue at Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is growing +7.6% versus a year earlier (3y avg +24.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570)?
Earnings per share at Daishin Balance No.8 Special Purpose Acquisition Co. Ltd are growing −13.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Daishin Balance No.8 Special Purpose Acquisition Co. Ltd (336570) carry?
The net debt of Daishin Balance No.8 Special Purpose Acquisition Co. Ltd is 4.5B KRW (fiscal year 2023, ≈ 0.1 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Daishin Balance No.8 Special Purpose Acquisition Co. Ltd in the live analysis

One click puts Daishin Balance No.8 Special Purpose Acquisition Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.